LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24HSDT&src=ctag” target=”_blank”gt;$HSDTlt;/agt; lt;a href=”https://twitter.com/hashtag/CLASSACTION?src=hash” target=”_blank”gt;#CLASSACTIONlt;/agt;–Glancy Prongay & Murray LLP (“GPM”) announces the continuation of its
investigation on behalf of Helius Medical Technologies, Inc. (“Helius”
or the “Company”) (NASDAQ: HSDT)
investors concerning the Company and its officers’ possible violations
of federal securities laws.
If you are a shareholder who suffered a loss, click here to
participate.
If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected],
or visit our website at www.glancylaw.com.
On April 10, 2019, Helius announced that the U.S. Food and Drug
Administration (“FDA”) declined the Company’s request for De Novo
classification and 510(k) clearance of the Company’s Portable
Neuromodulation Stimulator (PoNS™) device.
On this news, shares of Helius fell nearly 66% on April 10, 2019,
thereby injuring investors.
If you purchased Helius securities, have information, or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite
2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9224,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number, and the number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
www.glancylaw.com
[email protected]
